RayKnowChina Research Map
Shortlist0

Not yet recruitingMultiple myelomaN/A

Registered title, quoted from ClinicalTrials.gov

Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma

An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Renji Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorRenji Hospital上海交通大学医学院附属仁济医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06594211, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Relapsed or refractory after at least three prior lines of therapy, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies, with at least one complete cycle of treatment for each line, unless progressive disease (PD) was documented as the best response to that line.

    Inclusion criterion 5

    Male participants and females of childbearing potential must agree to use effective contraception from the time of signing the Informed Consent Form (ICF) until 2 years after receiving the study drug. Females of childbearing potential must have a negative serum pregnancy test prior to receiving the study drug.

    Inclusion criterion 22

    Participants who have previously received BCMA or GPRC5D targeted therapy, including but not limited to CAR-T, antibody-drug conjugates (ADCs), or bispecific antibodies, are allowed to participate in the study.

    Inclusion criterion 24

    Systemic corticosteroid therapy within 1 week prior to treatment, excluding the following: intranasal, inhaled, or local corticosteroids, local corticosteroid injections (such as intra-articular injections), systemic corticosteroid therapy at a daily dose not exceeding 10 mg of prednisone or its equivalent physiological dose, and corticosteroids used as premedication for allergic reactions.

    Exclusion criterion 6

    Prior antitumor therapy as follows, within the specified time frames prior to cell infusion: (a) Targeted therapy, proteasome inhibitors, or cytotoxic therapy within 2 weeks; (b) Immunomodulatory agent therapy within 1 week; (c) Monoclonal antibody treatment for multiple myeloma within 3 weeks; (d) Radiotherapy within 2 weeks. However, subjects are eligible irrespective of the end date of radiotherapy if the radiation field covered ≤ 5% of the bone marrow reserve.

    Exclusion criterion 7

    Prior therapy with any other investigational drugs or systemic anticancer treatments within 4 weeks prior to signing the ICF.

    Exclusion criterion 8

    History of another primary malignancy within 3 years prior to starting the study treatment, with exceptions for the disease under study, adequately treated basal or squamous cell carcinoma of the skin, and in situ cervical cancer.

    Exclusion criterion 9

  3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.

    Inclusion criterion 3

  4. Hemoglobin ≥ 80 g/L (without red blood cell transfusion within 7 days prior to testing; use of recombinant human erythropoietin is allowed).

    Inclusion criterion 13

    Platelet count ≥ 50 × 10\^9/L (without platelet transfusion or treatment with recombinant human thrombopoietin or thrombopoietin receptor agonists within 7 days prior to testing).

    Inclusion criterion 14

    Absolute neutrophil count (ANC) ≥ 0.75 × 10\^9/L (use of growth factors is allowed, but not within 7 days prior to testing).

    Inclusion criterion 15

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN).

    Inclusion criterion 16

    Creatinine clearance ≥ 40 mL/min, calculated based on the Cockcroft-Gault formula.

    Inclusion criterion 17

    Total bilirubin ≤ 2.0 × ULN; for participants with congenital bilirubin encephalopathy (such as Gilbert's syndrome), direct bilirubin must be ≤ 1.5 × ULN.

    Inclusion criterion 18

  5. Presence of uncontrollable active infections requiring parenteral antibacterials, antivirals, or antifungals; positivity for Hepatitis B surface antigen (HbsAg) or Hepatitis B core antibody (HbcAb), with detectable Hepatitis B Virus (HBV) DNA in peripheral blood; positivity for Hepatitis C Virus (HCV) antibody and HCV RNA in peripheral blood; positivity for TRUST test for syphilis; positivity for Human Immunodeficiency Virus (HIV) antibody.

    Exclusion criterion 2

  6. Pregnant or breastfeeding women; and subjects planning pregnancy within 2 years after signing the Informed Consent Form (ICF) until after receiving the study medication.

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06594211, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age between 18 to 75 years inclusive, with no gender restrictions.
  • Expected survival time exceeding 12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
  • Documented diagnosis of relapsed or refractory multiple myeloma (RRMM), and meets the following conditions:
  • Relapsed or refractory after at least three prior lines of therapy, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies, with at least one complete cycle of treatment for each line, unless progressive disease (PD) was documented as the best response to that line.
  • Disease progression during the most recent treatment or within 12 months.
  • Measurable disease at screening as defined by at least one of the following:
  • Serum M protein ≥ 5 g/L.
  • Urine M protein ≥ 200 mg/24h.
  • Involved serum free light chain ≥ 100 mg/L and abnormal serum free light chain κ/λ ratio.
  • Oxygen saturation ≥ 95% within 3 days prior to cell infusion.
  • Clinical laboratory values meeting the following criteria at screening:
  • Hemoglobin ≥ 80 g/L (without red blood cell transfusion within 7 days prior to testing; use of recombinant human erythropoietin is allowed).
  • Platelet count ≥ 50 × 10\^9/L (without platelet transfusion or treatment with recombinant human thrombopoietin or thrombopoietin receptor agonists within 7 days prior to testing).
  • Absolute neutrophil count (ANC) ≥ 0.75 × 10\^9/L (use of growth factors is allowed, but not within 7 days prior to testing).
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN).
  • Creatinine clearance ≥ 40 mL/min, calculated based on the Cockcroft-Gault formula.
  • Total bilirubin ≤ 2.0 × ULN; for participants with congenital bilirubin encephalopathy (such as Gilbert's syndrome), direct bilirubin must be ≤ 1.5 × ULN.
  • Corrected serum calcium ≤ 12.5 mg/dL (≤ 3.1 mmol/L) or ionized calcium ≤ 6.5 mg/dL (≤ 1.6 mmol/L).
  • For participants who meet the inclusion criteria at screening, red blood cell transfusion may be performed as needed after screening to maintain hemoglobin levels ≥ 80 g/L.
  • Deemed by the investigator to be able to receive lymphocyte-depleting chemotherapy.
  • Male participants and females of childbearing potential must agree to use effective contraception from the time of signing the Informed Consent Form (ICF) until 2 years after receiving the study drug. Females of childbearing potential must have a negative serum pregnancy test prior to receiving the study drug.
  • The participant can understand the study and has signed the ICF.
  • Participants who have previously received BCMA or GPRC5D targeted therapy, including but not limited to CAR-T, antibody-drug conjugates (ADCs), or bispecific antibodies, are allowed to participate in the study.

Exclusion Criteria:

  • Pregnant or breastfeeding women; and subjects planning pregnancy within 2 years after signing the Informed Consent Form (ICF) until after receiving the study medication.
  • Presence of uncontrollable active infections requiring parenteral antibacterials, antivirals, or antifungals; positivity for Hepatitis B surface antigen (HbsAg) or Hepatitis B core antibody (HbcAb), with detectable Hepatitis B Virus (HBV) DNA in peripheral blood; positivity for Hepatitis C Virus (HCV) antibody and HCV RNA in peripheral blood; positivity for TRUST test for syphilis; positivity for Human Immunodeficiency Virus (HIV) antibody.
  • Subjects deemed by the investigator to have significant dysfunction of vital organs (cardiovascular, pulmonary); subjects with gastrointestinal active bleeding within 3 months prior to signing the ICF; uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 95 mmHg), hypertensive crisis, or history of hypertensive encephalopathy; history or evidence of significant cardiovascular or cerebrovascular risk, including congestive heart failure (New York Heart Association class ≥ III), left ventricular ejection fraction < 50%, unstable angina, clinically significant arrhythmias (such as ventricular fibrillation, ventricular tachycardia, etc.); history of arterial thrombosis (such as stroke, transient ischemic attack) within 3 months prior to signing the ICF; history of symptomatic deep vein thrombosis, pulmonary embolism within 6 months prior to signing the ICF, or history of coronary artery angioplasty, defibrillation, or any clinical complications or diseases that may pose risks to the subject's safety or interfere with the study evaluation, procedures, or completion.
  • History or current evidence of any condition or disease that could interfere with the study results or, in the opinion of the investigator, is not in the best interest of the patient to participate.
  • Active central nervous system disease, or a history of the central nervous system requiring treatment (such as epilepsy); or subjects with central nervous system metastatic disease, leptomeningeal disease, or metastatic spinal cord compression.
  • Systemic corticosteroid therapy within 1 week prior to treatment, excluding the following: intranasal, inhaled, or local corticosteroids, local corticosteroid injections (such as intra-articular injections), systemic corticosteroid therapy at a daily dose not exceeding 10 mg of prednisone or its equivalent physiological dose, and corticosteroids used as premedication for allergic reactions.
  • Prior antitumor therapy as follows, within the specified time frames prior to cell infusion: (a) Targeted therapy, proteasome inhibitors, or cytotoxic therapy within 2 weeks; (b) Immunomodulatory agent therapy within 1 week; (c) Monoclonal antibody treatment for multiple myeloma within 3 weeks; (d) Radiotherapy within 2 weeks. However, subjects are eligible irrespective of the end date of radiotherapy if the radiation field covered ≤ 5% of the bone marrow reserve.
  • Prior therapy with any other investigational drugs or systemic anticancer treatments within 4 weeks prior to signing the ICF.
  • History of another primary malignancy within 3 years prior to starting the study treatment, with exceptions for the disease under study, adequately treated basal or squamous cell carcinoma of the skin, and in situ cervical cancer.
  • Subjects with a history or presence of interstitial lung disease or interstitial pneumonia.
  • Subjects planning to undergo autologous stem cell transplantation (ASCT) during the study.
  • Known hypersensitivity to any component of the anti-human BCMA×GPRC5D CAR-NK cell injection or the lymphodepletion regimen (cyclophosphamide and fludarabine).
  • Subjects who have undergone major surgery within 2 weeks or received live attenuated vaccines within 4 weeks prior to the pretreatment regimen.
  • Any investigator-assessed complications or other conditions that may affect a subject's ability to comply with the protocol or make them unsuitable to participate in the study.
  • Subjects with mental disorder who are unable to provide written ICF or comply with study procedures; or those unwilling or unable to adhere to study requirements.

Quoted from ClinicalTrials.gov, NCT06594211, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06594211, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06594211